Vcsa1 Gene Peptides for the Treatment of Inflammatory and Allergic Reactions

被引:9
作者
Morris, Katherine [1 ]
Kuo, Byron [2 ]
Wilkinson, Mark D. [2 ]
Davison, Joseph S. [3 ]
Befus, A. Dean [1 ]
Mathison, Ronald D. [3 ]
机构
[1] Univ Alberta, Fac Med & Dent, Dept Med, Heritage Med Res Ctr 550A, Edmonton, AB T6G 2S2, Canada
[2] Univ British Columbia, St Pauls Hosp, iCAPTURE Ctr Cardiovasc & Pulm Res, Dept Med Genet, Vancouver, BC V6Z 1Y6, Canada
[3] Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada
关键词
salivary glands; variable coding sequence multigene family; prohormone; peptides; inflammation; allergy; asthma; endotoxemia; neutrophils; leukocytes; adhesion; superoxide anion; protein kinase C;
D O I
10.2174/187221307780979892
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The recently emerged Vcsa1 gene is one member of the variable coding sequence (VCS) multigene family of Rattus norvegicus. This gene encodes the precursor prohormone SMR1 (submandibular rat-1), which on enzymatic processing gives rise to several 5 to 11 amino acid peptides that modulate a variety of physiological functions. The analgesic pentapeptide sialorphin and anti-inflammatory heptapeptide submandibular gland peptide-T (TDIFEGG) are the most intensively studied. Although the Vcsa1 gene and its protein product are unique to rats, TDIFEGG or a derivative acts on all species examined to date, including human cells, in functions related to allergic reactions and inflammation. In this review, the patent and academic literature on SMR1 and its natural peptides and their derivatives are reviewed for consideration of biological targets and relevance to the development of novel therapeutic agents. The VCS gene family is discussed and we speculate on possible human homologs of these potent anti-inflammatory rat-derived peptides. The biologically active peptide products of SMR1 are considered and the mechanism of action and structure-activity relationships of the anti-inflammatory submandibular gland peptide-T and its derivatives are discussed.
引用
收藏
页码:124 / 132
页数:9
相关论文
共 96 条
  • [31] Increase of Fas-induced apoptosis by inhibition of extracellular phosphorylation of Fas receptor in Jurkat cell line
    Lautrette, C.
    Loum-Ribot, E.
    Petit, D.
    Vermot-Desroches, C.
    Wijdenes, J.
    Jauberteau, M. O.
    [J]. APOPTOSIS, 2006, 11 (07) : 1195 - 1204
  • [32] The regulation of integrin function by Ca2+
    Leitinger, B
    McDowall, A
    Stanley, P
    Hogg, N
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2000, 1498 (2-3): : 91 - 98
  • [33] Two functional states of the CD11b A-domain:: Correlations with key features of two Mn2+-complexed crystal structures
    Li, R
    Rieu, P
    Griffith, DL
    Scott, D
    Arnaout, MA
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 143 (06) : 1523 - 1534
  • [34] Attenuation of intestinal and cardiovascular anaphylaxis by the salivary gland tripeptide FEG and its D-isomeric analog feG
    Mathison, R
    Lo, P
    Moore, G
    Scott, B
    Davison, JS
    [J]. PEPTIDES, 1998, 19 (06) : 1037 - 1042
  • [35] TEMPORAL ANALYSIS OF THE ANTIINFLAMMATORY EFFECTS OF DECENTRALIZATION OF THE RAT SUPERIOR CERVICAL-GANGLIA
    MATHISON, R
    CARTER, L
    MOWAT, C
    BISSONNETTE, E
    DAVISON, JS
    BEFUS, AD
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (05): : R1537 - R1543
  • [36] ROLE FOR THE SUBMANDIBULAR-GLAND IN MODULATING PULMONARY INFLAMMATION FOLLOWING INDUCTION OF SYSTEMIC-ANAPHYLAXIS
    MATHISON, R
    HOGAN, A
    HELMER, D
    BAUCE, L
    WOOLNER, J
    DAVISON, JS
    SCHULTZ, G
    BEFUS, D
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 1992, 6 (02) : 117 - 129
  • [37] The tripeptide feG reduces endotoxin-provoked perturbation of intestinal motility and inflammation
    Mathison, R
    Lo, P
    Tan, D
    Scott, B
    Davison, JS
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2001, 13 (06) : 599 - 603
  • [38] Regulation of leukocyte adhesion to heart by the tripeptides feG and feG(NH2)
    Mathison, R
    Woodman, R
    Davison, JS
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (09) : 785 - 792
  • [39] Mathison R., 2005, [No title captured], Patent No. [US20056852697, 20056852697]
  • [40] Mathison R, 2007, P W PHARM SOC, V50